Xuanzhu Biopharmaceutical Co., Ltd.
Registry sponsor category
Industry
- Other names
- Xuanzhu Biopharmaceutical Co., Ltd.
- Company name
- Xuanzhu Biopharmaceutical Co., Ltd.
- Organisation type
- Industry
- Registry sponsor category
- Industry
- Publicly traded (proxy)
- No
- Listing at source
- Listed
Related records
Trials (24)
- A Clinical Trial of Anaprazole for Treating Reflux Esophagitis.
- A Clinical Trial of XZP-3287 for Material Balance
- A Clinical Trial of XZP-6019 Tablets in Healthy Subjects
- A Phase I Clinical Trial of XZP-5610 Tablets in Healthy Subjects
- A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer
- A Study of Anaprazole Sodium Enteric-coated Tablets in the Treatment of Reflux Esophagitis
- A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors.
- A Study of KM501 in Patients With Solid Tumors
- A Study of KM602 in Patients With Advanced Solid Tumors
- A Study of the Absorption, Metabolism and Excretion of [14C]XZP-3621 in Human
- A Study of the Pharmacokinetics and Safety of Anaprazole Sodium in Special Populations
- A Study of XZB-0004 in Patients With Solid Tumors
- A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer
- A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer
- A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC
- A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors
- A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib
- Drug-drug Interaction Study of Rifampin and Anaprazole Sodium
- Drug-drug Interaction Study of XZP-3621 Tablet
- Effect of Clarithromycin and Rifampicin on the Pharmacokinetics of XZP-3287 in Healthy Subjects